AUM BioTech - Self-Delivering FANA Oligos for RNA Silencing





  • Easy silencing or regulation of mRNA, miRNA or long non-coding RNA targets
  • No need to use transfection reagents - Ideal for difficult-to-transfect cells and animal models
  • Superior potency, high stability and target binding affinity
  • Enhanced nuclease resistance and duration of activity
  • Custom-designed oligos for high efficiency and efficacy
  • Highly cost-effective

Introductory Offer*
Buy 3 FANA Oligos for your Target Gene, and Get the 4th Free.

*Offer subject to change.  The 4 oligos must be for the same gene.





USDA and AUM BioTech Develop a Novel Non-GMO RNA Silencing Approach Against Citrus Greening

Researchers at the USDA are now using AUM's next-generation RNA silencing FANA technology to combat the plant pathogenic bacteria Candidatus Liberibacter and citrus pests like citrus root weevil and Asian citrus psyllid.  Although AUM's FANA technology works at the genetic level, it does not create genetically modified organisms.  Preliminary results showed an increase in insect mortality and a reduction of bacteria within citrus trees.  This is the first evidence of successful delivery of FANA Antisense Oligonucleotides (FANA ASOs) into plants through foliar sprays, root absorption and tree trunk injections; and provides a new approach for management of agricultural pests and plant pathogens.  FANA ASOs do not require the use of transfection reagents.  These encouraging results suggest that AUM's FANA technology offers great potential to be developed for insect and plant pathogen management for a wide spectrum of agricultural crops. The data will be presented at the upcoming International Plant & Animal Genome XXV conference, in San Diego, California in January of 2017.

Click here to read more (link to PRNewswire).


Award Presented for a New Approach to Combat HIV by Using FANA RNA Silencing Technology to Inhibit HIV Replication

Dr. Mayumi Takahashi of the Beckman Research Institute at City of Hope in California was selected for the prestigious Dr. Alan Gewirtz Award Scholarship for her work. In her talk Dr. Takahashi showed that FANA ASOs can effectively target HIV by self-delivery (free uptake; gymnosis) into primary peripheral blood mononuclear cells (PBMCs) taken from different patient donors without causing immune response and toxicity. Along with impressive IC50 values the data also showed potent inhibition of HIV for two weeks by a single dose. Dr. Takahashi also presented important and interesting mechanistic data for this approach to inhibit HIV replication.  This work was done in the laboratory of Dr. John Rossi who is a distinguished scientist working on the development of RNA targeting therapies for HIV and his expertise is globally recognized. Dr. Rossi is the Lidow Family Research Chair and Morgan & Helen Chu Dean's Chair of the Irell & Manella Graduate School at Beckman Research Institute at City of Hope in California. 

Click here to read more (link to PRNewswire).
Click here for the video of the presentation (link to youtube).


FANA RNA Silencing Technology Showcased in Several Studies at the 2016 Oligonucleotide Therapeutics Society Meeting

Data on the use of FANA RNA silencing technology was recently presented by several of AUM's academic collaborators at the 2016 Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal, Canada.  The poster presenters were also selected for travel grants for this meeting.  Click here to read more (link to PRNewswire).

  • AUM FANA antisense technology was shown to offers high specificity and efficacy for allele specific silencing in certain neurodegenerative disorders by Dr. Haiyan Zhou from University College London, UK.
 This work was done in the laboratory of Dr. Francesco Muntoni. Dr. Muntoni is the Chair of Paediatric Neurology at University College London's Institute of Child Health and has lead several clinical trials for rare diseases.
  • Gymnotically delivered (self-delivered) FANA antagomirs targeted against miR130b were shown to reduce cancer cell motility and block cancer cell attachment to vascular walls in vivo by Dr. Lian Willets from the University of Alberta, Canada.
 This work was done in the laboratory of Dr. John Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta, Canada.


Research Article Recently Published in Nature Publishing Group's Molecular Therapy—Nucleic Acids

  • A certain variation of FANA oligos was shown to effectively downregulate both mRNA and protein expression of Bcl-2 in a difficult-to-transfect polarized epithelial cell monolayer in the absence of any delivery agent. Compared to conventional siRNAs and other oligo chemistries, FANA oligos were found to be most potent, efficient and caused no toxicity.  This study was done in the laboratory of  Dr. Jean-Christophe Leroux, Professor at ETH Zurich Switzerland in collaboration with Dr. Masad Damha who is the James McGill Professor and Chair of the Department of Chemistry at McGill University in Canada.  
Click here for the research paper (link to Nature Research).





    AUMsilence self delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection reagents. Especially designed for primary cells and very difficult to transfect cell types. Ideal for animal studies. Suited for fish and amphibian model systems as well. 
    Highly recommended as a replacement for siRNAs or other oligonucleotide approaches.

    AUMantagomir self transfecting oligos serve as potent antagomirs by binding with miRNAs and prevent their hybridization with their target mRNAs.

    AUMmirblocker self transfecting oligos serve as competitive blockers/decoys against miRNAs to inhibit their binding with target mRNA.  AUMmirblocker oligos will bind with the targeted regions on the mRNA and inhibit binding of miRNA with the mRNA.

    AUMlnc oligos achieve potent RNase H-mediated cleavage of the target long non-coding RNA.

    AUMskip oligos make suitable candidates for exon skipping experiments.

    AUMblock oligos act as steric blockers and inhibit translation elongation. AUMblock oligos act as decoys and repress protein expression and do not induce mRNA cleavage.

    AUMprobes serve as excellent probes or decoys to suit a wide variety of experimental applications.